HUP0001939A2 - Kemoterápiás szert és egy benzimidazolszármazékot és adott esetben egy potenciátort tartalmazó gyógyszerkészlet daganatok növekedésének gátlására - Google Patents

Kemoterápiás szert és egy benzimidazolszármazékot és adott esetben egy potenciátort tartalmazó gyógyszerkészlet daganatok növekedésének gátlására

Info

Publication number
HUP0001939A2
HUP0001939A2 HU0001939A HUP0001939A HUP0001939A2 HU P0001939 A2 HUP0001939 A2 HU P0001939A2 HU 0001939 A HU0001939 A HU 0001939A HU P0001939 A HUP0001939 A HU P0001939A HU P0001939 A2 HUP0001939 A2 HU P0001939A2
Authority
HU
Hungary
Prior art keywords
benzimidazole
cancers
potentiator
inhibiting
kit
Prior art date
Application number
HU0001939A
Other languages
English (en)
Inventor
James Berger Camden
Original Assignee
The Procter & Gamble Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Co. filed Critical The Procter & Gamble Co.
Publication of HUP0001939A2 publication Critical patent/HUP0001939A2/hu
Publication of HUP0001939A3 publication Critical patent/HUP0001939A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Atalálmány célját egy eljárás képezi, emlősökben - különösenemberekben és meleg vérű állatokban - rákok és tumorok elterjedésénekgátlására. Az eljárás a tumor méretét csökkentő kemoterápiás szerek ésbenzimidazolszármazék - előnyösen carbendazim vagy 2-metoxi-karbonil-amino-benzimidazol - bármilyen sorrendben egymást követő beadásáttartalmazza. Abenzimidazol előnyösen a rákos sejtvonalak apoptózisát(programozott elhalását) eredményezheti, ezáltal csökkenti a rákossejtek újranövekedését. Atalálmány szerinti gyógyszerkészletben akemoterápiás anyag gyógyszer körülbelül 3-14napos kezelési adagban, ésa benzimidazolvegyület, előnyösen 2-metoxi-karbonil-amino-benzimidazolkörülbelül 3-365 napos adagban van. Ó
HU0001939A 1997-01-28 1998-01-21 Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator HUP0001939A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/788,482 US5900429A (en) 1997-01-28 1997-01-28 Method for inhibiting the growth of cancers

Publications (2)

Publication Number Publication Date
HUP0001939A2 true HUP0001939A2 (hu) 2001-01-29
HUP0001939A3 HUP0001939A3 (en) 2002-08-28

Family

ID=25144634

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001939A HUP0001939A3 (en) 1997-01-28 1998-01-21 Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator

Country Status (19)

Country Link
US (3) US5900429A (hu)
EP (1) EP0967977A1 (hu)
JP (1) JP2001509164A (hu)
KR (1) KR20000070551A (hu)
CN (1) CN1244123A (hu)
AR (1) AR011583A1 (hu)
AU (1) AU729099B2 (hu)
BR (1) BR9807003A (hu)
CA (1) CA2277166A1 (hu)
CZ (1) CZ265499A3 (hu)
HU (1) HUP0001939A3 (hu)
ID (1) ID23507A (hu)
IL (1) IL131097A0 (hu)
NO (1) NO993654L (hu)
PL (1) PL335054A1 (hu)
SK (1) SK99199A3 (hu)
TR (1) TR199901768T2 (hu)
WO (1) WO1998032440A1 (hu)
ZA (1) ZA98643B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) * 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
DE19710907A1 (de) * 1997-03-15 1998-09-17 Pascoe Pharm Praeparate Gmbh Ascorbinsäure als Adjuvans in der Chemo- und Strahlentherapie von Malignomen
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
CA2362047A1 (en) * 1999-02-26 2000-08-31 Larry Helson Treatment regimen for prostate cancer, initiated after androgen ablative therapy has started
WO2000050022A2 (en) * 1999-02-26 2000-08-31 Napro Biotherapeutics, Inc. Treatment regimen for hormone-sensitive cancers
JP2003524624A (ja) * 1999-04-09 2003-08-19 ジェシー エル エス オウ 治療薬の組織への送達を高める方法及び組成物
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6423734B1 (en) * 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
CA2401304A1 (en) * 2000-03-02 2001-09-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
AU2002248341B8 (en) * 2001-01-11 2007-03-29 Board Of Regents, The University Of Texas System Antihelminthic drugs as a treatment for hyperproliferative diseases
US6515074B2 (en) * 2001-01-22 2003-02-04 Delphi Technologies, Inc. Thermoplastic polymer alloy compositions and process for manufacture thereof
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
DK1407784T3 (da) * 2001-06-25 2011-02-28 Ajinomoto Kk Antitumormidler
EP1830847B1 (en) * 2004-12-06 2014-11-19 Pitney Pharmaceuticals Pty Limited Treatment for cancer
CN100350975C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 抗癌药物组合物
EP2131840B1 (en) * 2007-03-07 2018-10-17 MEI Pharma, Inc. Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
EP3621603A4 (en) 2017-05-08 2021-01-20 Meharry Medical College HYDROXYUREA SERVING TO IMPROVE SPERMATIC CELLS

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010968A (en) * 1959-11-25 1961-11-28 Du Pont Process for manufacture of certain alkyl esters of benzimidazole carbamic acids
NL134354C (hu) 1963-05-23
US3499761A (en) 1964-07-20 1970-03-10 Gaf Corp Silver halide emulsions containing alkyl esters of benzimidazole carbamic acid antifogging agents
US3541213A (en) 1966-05-06 1970-11-17 Du Pont Fungicidal and mite ovicidal substituted 2-aminobenzimidazoles
US3881014A (en) 1968-11-05 1975-04-29 Bayer Ag N-tritylimidazoles for treating fungal infections
BE759337A (fr) * 1969-11-24 1971-05-24 Lilly Co Eli Benzimidazol (2,1-b)-quinazolin (6h) ones qui sont des immuno-depresseurs, et nouvelles benzimidazo (2,1-b) quinazolin-12-(6h) ones
US3956262A (en) * 1970-12-09 1976-05-11 Beecham Group Limited Triazenoimidazoles
US3738995A (en) * 1971-05-14 1973-06-12 Du Pont Solvent process for the preparation of 1 - carbamoyl-substituted 2 - benzimidazolecarbamates
FR2155888A1 (en) * 1971-10-13 1973-05-25 Agot Aime Solid anthelmintic composn - for more economical treatment of ruminants
US4046906A (en) * 1973-04-21 1977-09-06 Hoechst Aktiengesellschaft Salts of alkyl 2-benzimidazole-carbamate
HU193951B (en) * 1985-03-11 1987-12-28 Richter Gedeon Vegyeszet Process for producing new sulfur-containing 5-substituted benzimidazol derivatives and pharmaceutical compositions containing them
US4731366A (en) * 1986-08-05 1988-03-15 Harbor Branch Oceanographic Institution, Inc. Discorhabdin compositions and their methods of use
GB2210875B (en) * 1987-10-09 1991-05-29 Farmos Oy Aromatase inhibiting 4(5)-imidazoles
US5329012A (en) * 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
US5114951A (en) 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance
US5149527A (en) * 1990-09-18 1992-09-22 Oncotech, Inc. Immunopotentiating protocol for chemotherapy-responsive tumors
US5310748A (en) * 1992-05-11 1994-05-10 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
US5364875A (en) * 1992-05-11 1994-11-15 The Du Pont Merck Pharmaceutical Company Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis
US5290801A (en) * 1992-05-29 1994-03-01 The Du Pont Merck Pharmaceutical Company Benzimidazoles for the treatment of atherosclerosis
EP0655066A1 (en) * 1992-08-12 1995-05-31 PHARMACIA & UPJOHN COMPANY Protein kinase inhibitors and related compounds combined with taxol
CN1090186C (zh) 1993-03-31 2002-09-04 麦克公司 治疗aids药物组合物中的hiv蛋白酶抑制剂
US5434163A (en) 1993-05-14 1995-07-18 The Medical College Of Pennsylvania Treatment of Cryptococcus neoformans infection
JP3213471B2 (ja) * 1994-04-13 2001-10-02 ポーラ化成工業株式会社 薬効成分含有リポソーム製剤の製造方法
ZA962879B (en) * 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
US5629341A (en) * 1995-04-12 1997-05-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5656615A (en) 1995-04-12 1997-08-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
ZA962880B (en) 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
NZ305784A (en) * 1995-04-12 2001-03-30 Procter & Gamble Benzimidazole containing medicaments for treating cancers, tumors and viral infections
US5665713A (en) * 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
AU714056B2 (en) 1995-04-12 1999-12-16 Uaf Technologies And Research Llc A pharmaceutical composition containing N-chlorophenylcarbamates and N-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers
US5665751A (en) 1995-06-07 1997-09-09 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
MX9707809A (es) * 1995-06-07 1998-01-31 Procter & Gamble Una composicion farmaceutica que contiene bencimidazol para inhibir el crecimiento de canceres.
KR19990022617A (ko) 1995-06-07 1999-03-25 데이비드 엠 모이어 백혈병 치료용 약제의 제조를 위한 벤즈이미다졸의 용도
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6200992B1 (en) 1995-06-07 2001-03-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
PL324905A1 (en) 1995-08-03 1998-06-22 Procter & Gamble Application of griseofulvin in carcinoma development inhibition
IL123095A0 (en) 1995-08-04 1998-09-24 Procter & Gamble Pharmaceutical compositions containing fluconazole for inhibiting the growth of cancers
US5908855A (en) 1996-07-16 1999-06-01 The Procter & Gamble Company Compositions for treating viral infections
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
PE11499A1 (es) 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment

Also Published As

Publication number Publication date
NO993654D0 (no) 1999-07-27
CN1244123A (zh) 2000-02-09
CZ265499A3 (cs) 1999-12-15
EP0967977A1 (en) 2000-01-05
US5900429A (en) 1999-05-04
HUP0001939A3 (en) 2002-08-28
AU6034398A (en) 1998-08-18
JP2001509164A (ja) 2001-07-10
IL131097A0 (en) 2001-01-28
BR9807003A (pt) 2000-03-14
AU729099B2 (en) 2001-01-25
CA2277166A1 (en) 1998-07-30
KR20000070551A (ko) 2000-11-25
WO1998032440A1 (en) 1998-07-30
NO993654L (no) 1999-09-28
ZA98643B (en) 1998-07-30
TR199901768T2 (xx) 1999-09-21
US6329355B1 (en) 2001-12-11
AR011583A1 (es) 2000-08-30
ID23507A (id) 2000-04-27
PL335054A1 (en) 2000-03-27
SK99199A3 (en) 2000-05-16
US6271217B1 (en) 2001-08-07

Similar Documents

Publication Publication Date Title
HUP0001939A2 (hu) Kemoterápiás szert és egy benzimidazolszármazékot és adott esetben egy potenciátort tartalmazó gyógyszerkészlet daganatok növekedésének gátlására
NO20010887D0 (no) Quinazolin derivater
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
HUP0003194A2 (hu) Triozin-kináz-gátló alkalmazása prosztatarák kezelésére szolgáló szinergista gyógyszerkészítményben
UY25074A1 (es) Inhibidores de la farnesil proteina transferasa
UA50719C2 (uk) Проліки для терапії пухлин і запальних захворювань
HUP0104669A2 (hu) Sugárkezelés és COX-2 gátló kombinációs terápia daganatok kezelésére
NZ334540A (en) Use of cetrorelix as a LH-RH antagonist for treating prostate hypertrophy and prostate cancer
NO975661L (no) Anvendelse av bis-1,2,4-triazoler for fremstilling av et medikament for behandling av cancer
TR200001147T2 (tr) Kanser ve makular dejenerasyonun tedavisi için makrolidlerin kullanımı
FR08C0001I2 (hu)
DE3850007D1 (de) Tumor- oder krebszelltötende Therapie und demgemäss verwendbare Wirkstoffe.
NO974696D0 (no) Farmasöytisk preparat inneholdende N-klor-fenylkarbamater og N-klorfenyltiokarbamater for inhibering av vekst av virus og cancer
HUP9903506A2 (hu) Grizeofulvin felhasználása rákok növekedésének gátlására
AR003174A1 (es) Una composicion farmaceutica que comprende un portador farmaceuticamente aceptable y un agente quimioterapeutico y un triazol, dicha composicion farmaceutica que comprende un potenciador, uso de un agente quimioterapeutico y un 1h-1,2,4-triazol y uso de un potenciador y dicho triazol para tratar cancer, tumor o infecciones virales en mamiferos de sangre caliente
AU2002357191A1 (en) Derivatives of isoindigo, indigo and indirubin and use in treating cancer
ATE383863T1 (de) Kombinationschemotherapie
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
AR014640A1 (es) UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE.
CA2454664A1 (en) Cancer treatment with go6976 and its related compounds
ATE223209T1 (de) Propargylamin enthaltende zusammensetzung zur verbesserung der krebstherapie
Chu et al. Radiosensitizers and protectors
IT1306187B1 (it) Metodo per l'eradicazione selettiva di cellule tumorali aventi lafunzione di p53 inattiva.
MX9707810A (es) Una composicion farmaceutica que contiene derivados de n-fosfonoglicina para inhibir el crecimiento de virus y canceres.